论文部分内容阅读
根据CADRMP(加拿大药物不良反应监测中心)收到的与非典型抗精神抑郁药有关的葡萄糖代谢紊乱的病例报告,加拿大市售产品评价局建议,使用抗精神抑郁药的患者需进行葡萄糖代谢常规监测。至2001年6月7日,CADRMP已经收到37例怀疑是服用氯氮平(clozapine)、奥氮平(olanzap-ine)、喹硫平(quetiapine)、利培司酮(risperidome)所致的糖代谢紊乱的病例报告(见表)。患者年龄为11～78岁,治疗的时间为118天～6.5年(其中17人<5个月)。氯氮平的治疗剂量是100～775mg·d~(-1)(n=17),奥氮平是7.5～30mg·d~(-1)(n=10),喹硫平300～
According to a case report of a disorder of glucose metabolism associated with atypical antidepressants received by CADRMP (Canadian Center for Adverse Drug Reaction Monitoring), the CEPA recommended that patients with antidepressants be routinely monitored for glucose metabolism . As of June 7, 2001, CADRMP had received 37 patients suspected of taking clozapine, olanzapine, quetiapine, risperidome Case reports of disorders of glucose metabolism (see table). The patients were 11 to 78 years old and the duration of treatment was 118 days to 6.5 years (17 of whom <5 months). The therapeutic dose of clozapine was 100-775 mg · d -1 (n = 17), olanzapine was 7.5-30 mg · d -1 (n = 10), quetiapine was 300 ~